Business
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and
About this update from Oruka Therapeutics, Inc.
[{"type":"text","content":"AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020 WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the second quarter of 2020 and provided a corporate update.\n\n \n \n \n \n \n \n \n \n \n \n \n Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc.\n \n \n \n \n \n \n \n \n\n Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “As the SARS-CoV-2 pandemic has progressed, serious complications relating to over-activation of the coagulation and immune systems have increasingly been observed in patients hospitalized with severe disease. Based on previous and emerging work on mechanisms of virus pathogenesis, we believe this evidence implicates involvement of tissue factor pathways, of which AB201 is a potent and long-acting inhibitor, providing a strong rationale to evaluate AB201 as a potential therapeutic for COVID-19. With this rationale along with significant safety data from prior human clinical trials, we look forward to initiating Phase 2 clinical development later this year.” Pipeline Update AB201 (rNAPc2) – a small recombinant protein being developed as a potential treatment for RNA virus associated disease, initially focusing on COVID-19. Initiated planning for development of AB201 as a potential treatment for patients with severe COVID-19.Clinical collaboration established with the Colorado Prevention Center, the University of Colorado's Academic Research Organization.The Company anticipates filing an Investigational New Drug (IND) application for AB201 as a potential treatment for COVID-19 with the U.S. Food and Drug Administration (FDA) in third quarter of this year.Pending FDA concurrence, ARCA estimates initiating Phase 2 clinical testing of AB201 in the fourth quarter of this year. GencaroTM (bucindolol hydrochloride) - a pharmacologically unique beta-blocker and mild vasodilator being developed as a potential genetically targeted treatment for atrial fibrillation (AF) in patients with heart failure (HF). Initiation of...